The Future of Cancer Diagnostics: Where Liquid Biopsy Goes Next
Over the past decade, liquid biopsy has been moving from a research concept to a clinical reality. ctDNA testing is used in clinical practice to detect residual disease and monitor treatment response. Although CTC enumeration has long been an FDA-recognised prognostic biomarker in metastatic breast cancer, the technology overall is approaching a significant inflection point- one that may deliver on its initial promise of reliable, large-scale detection and ongoing analysis of tumour biology.
The trajectory is upward. The next decade of liquid biopsy development promises to be more significant still. Here is where the field is heading — and what it means for patients, clinicians, and the cancer diagnostics landscape.
Multi-cancer early detection
The most ambitious application of liquid biopsy technology is multi-cancer early detection (MCED)- the ability to screen for multiple cancer types simultaneously from a single blood draw.
Several large-scale MCED tests are now in clinical development or early commercial deployment. These tests analyse patterns of ctDNA methylation or other biomarkers to detect cancer signals and, in some cases, identify the tissue of origin. Early data is promising: some approaches have demonstrated the ability to detect cancers for which no standard screening currently exists, including pancreatic, ovarian, and oesophageal cancer.
The public health implications of this are significant. Many cancers are currently diagnosed late precisely because there is no routine screening programme. MCED has the potential to change that fundamentally.
AI-assisted analysis
The volume and complexity of data generated by liquid biopsy testing creates a challenge that artificial intelligence is increasingly well-placed to address. Machine learning models are being developed to analyse CTC morphology, ctDNA patterns, and multi-omic data in ways that go beyond what manual analysis can achieve.
In CTC testing specifically, AI-assisted image analysis can improve the accuracy of cell identification, reduce false positives, and extract biological information from cell characteristics that would otherwise be difficult to quantify. This is not a future aspiration — it is an active area of development with early clinical applications already emerging.
Expanding beyond cancer
Liquid biopsy technology developed for oncology is beginning to find applications beyond cancer. Cell-free DNA analysis is being explored in prenatal testing, organ transplant monitoring, and cardiovascular disease. The underlying technology — detecting and analysing biological material circulating in blood — has applications wherever biological change needs to be tracked non-invasively over time.
The regulatory and commercial landscape
The regulatory pathway for liquid biopsy tests is maturing. In the UK, the MHRA is developing frameworks for innovative diagnostics. In the EU, the In Vitro Diagnostic Regulation (IVDR) sets a rigorous standard for diagnostic test approval. In the US, the FDA has established clear criteria for liquid biopsy test evaluation, and several tests have received breakthrough device designation.
Investment in liquid biopsy companies has grown substantially, and established diagnostics companies are acquiring or partnering with innovative developers. The market opportunity is substantial — and the clinical need it addresses is clear.
Where Frontier Diagnostics fits in
At Frontier Diagnostics, we are focused on CTC technology- albeit at the pre-RUO stage- specifically the analysis of whole tumour cells in the bloodstream. We believe this remains one of the most clinically rich applications of liquid biopsy technology, and that the information available from intact cancer cells goes beyond what genetic fragment analysis alone can provide.
The field is moving quickly. The science is advancing, the evidence base is growing, and the clinical case is becoming harder to ignore. We are committed to being at the forefront of that progress.
